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1. Introduction 
Previous work from this laboratory demonstrated 
that there is an ordered pattern of metabolic imbalance 
in the spectrum of hepatomas of different growth 
rates that is expressed in enzymatic alterations 
linked with malignant transformation and progression 
[ 1,2] . Recent investigations showed that phospho- 
fructokinase, a proliferation-linked enzyme (in this 
class are enzymes the activity of which is elevated or 
decreased in parallel with tumor growth rate and 
malignancy), was increased in both activity and 
concentration in hepatomas [3,4]. It appears that 
no evidence has been published that malignant- 
transformation-linked enzymes (in the class are 
grouped enzymes that are altered in the same 
direction in all the hepatomas) also exhibited an 
increase in enzyme concentration. This work brings 
such evidence reporting that glucose 6-phosphate 
dehydrogenase (G6P DH) (EC 1.1.1.49) the first 
committed enzyme of pentose phosphate biosynthesis, 
was present in increased concentration in the 
hepatomas. This evidence is provided by separate 
techniques independently assaying the total enzyme 
activity and titrating with anti-enzyme serum the 
immunoprecipitable enzyme protein concentration. 
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Thus, the enzymatic alterations linked with tumor 
progression (phosphofructokinase) and linked with 
transformation (G6P DH) represent the reprogramming 
of gene expression as manifested in the hepatomas. 
2. Materials and methods 
2.1. Animals and preparation of tissue extracts 
Normal male Wistar rats weighing 200 to 240 g 
and normal male AU/N and tumor-bearing ACI/N 
rats (bilateral subcutaneous transplants) weighing 
160- 180 g were used. The animals were kept in 
individual cages. Purina laboratory chow and tap 
water were available ad libitum, except when the 
animals were put on starvation or on a high 
carbohydrate diet to induce G6P DH [5]. New 
Zealand adult male albino rabbits were used for 
production of the antiserum. Rats were stunned, 
decapitated and exsanguinated. Liver or tumor was 
immediately removed and minced. A homogenate 
was made in 3 vol of a medium containing KC1 
(1.54 mM), Tris-HCl(50 mM, pH 8.0) and EDTA 
(1 mM) [6] . The homogenate was centrifuged at 
25 000 g for 1 h and the resulting supernate was used 
for enzyme purification. For immunochemical 
titration the 100 000 g (30 min) supernate was used. 
2.2. Purification of liver and hepatoma G6P DH 
Previously published methods [7] were 
adapted for the extraction of the enzyme in our 
liver and hepatoma systems. The modifications we 
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introduced are given below. In the present extraction 
procedure instead of DEAE-cellulose and CM- 
cellulose, BEAE-Sephadex and CM-Sephadex columns 
were used. The DEAE Sephadex column was 
equilibrated with Tris-HCl buffer (50 mM, pH 8.0). 
After the sample application the column was 
washed with 100 mM of NaCl gradient in the 
equilibrating buffer and the enzyme was eluted 
with 3.50 mM NaCl in the same buffer. The ammonium 
sulfate-treated redissolved precipitate was dialyzed 
against the Tris buffer containing NADP’ (0.12 mM) 
instead of distilled water. Na-acetate buffer (50 mM, 
pH 5.5) containing NADP’ (0.12 mM) was used for 
the equilibration of the CM-Sephadex column. The 
enzyme was eluted with 100 mM NaCl containing 
G6P(0.15 mM) in Na-acetate buffer (50 mM, pH 6.5). 
Before the enzyme elution, the column was washed 
with 50 mM NaCl in the equilibrating buffer. The 
conditions for the second DEAE-Sephadex chromato- 
graphy were the same as for the first one except 
that both the equilibrating buffer and the gradients 
contained NADP’ (0.12 mM) and before the final 
elution (350 mM NaCl) the column was washed 
with 100 and 200 mM of NaCl gradient, respectively. 
The procedure for the hepatoma enzyme extraction 
and purification was identical. 
2.5. Double-diffusion method 
This procedure was performed as described by 
Ouchterlony [lo] using 0.75% agarose (Bio-Rad 
Laboratories, Richmond, Calif.) suspended in Tris 
buffer (50 mM, pH 8.0). The plates were incubated 
for 24 h at room temperature and the precipitine 
lines were stained either for proteins (Buffalo black) 
or enzyme activity. 
2.6. Immunochemical titration 
Enzyme samples were incubated in duplicates 
for 45 min at 37°C in a final vol of 0.5 ml in 
presence of Tris-HCl buffer (5 mM, pH 8.0) 
NADP+ (0.24 mM) and different amounts of 
antiserum or control serum. Hepatoma extracts were 
brought to about the same activity as that of the 
liver to achieve complete neutralization and values 
were corrected for this dilution. The samples were 
kept at 5°C overnight and centrifuged the next 
morning (40 0001: for 20 min); activities were 
assayed in the supernates. 
3. Results and discussion 
3.1. Purification of G6P DH from normal and 
neoplastic liver 
Purification methods were adapted to the liver 
2.3. Enzyme assays and protein 
G6P DH activity was determined spectrophoto- 
metrically at 37°C as cited elsewhere [8] . The 
enzyme unit is the activity that metabolizes 1 
pmol of substrate per min at 37°C. Protein content 
was measured by the method of Lowry et al. [9]. 
and hepatoma systems in this Laboratory. The 
enzyme was purified from the liver of refed rats 
176-fold and from hepatoma 3924A, 74-fold. 
The final specific activities for the liver and the 
hepatoma enzyme were 55.3 and 1 1,9 pmol/mg 
protein/mitt, respectively. 
3.2. Comparisorr of kinetic properties of purified 
2.4. Production ofantiserum G6P DH from liver and hepatoma 3924A (table I) 
Fifty units of the purified enzyme were According to studies carried out on purified 
emulsified with an equal vol of Freund’s complete G6P DH from liver and hepatoma the enzyme 
adjuvant (Difco Laboratories, Detroit, Michigan) and preparations were indistinguishable on the basis of 
injected subcutaneously into the scapular region kinetic properties. 
of rabbits on the 1st day and into the thigh on the 
7th day. Three weeks after the first injection a 3.3. Inhibition by hemoglobin, methemoglobin and 
booster injection of the same amount of enzyme my oglo bin 
was given intravenously without the adjuvant. One week Earlier reports indicated that hemoglobin may 
after the last injection blood samples were taken affect the structure [ 1 l] or inhibit the activity 
from the ear and when antibody titer was sufficiently [ 121 of G6P DH. The observations in table 1 
high, the antiserum was collected and stored at -20°C. indicate that hemoglobin (from beef blood, Type 1, 
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Table 1 
Comparison of the kinetic properties of purified rat liver and 
hepatoma glucose 6-phosphate dehydrogenasc 
Modulators 
Glucose 6-phosphate, KM 
NADP+, KM 
llcmoglobin, I,, 
Inhibition by NADPH 
Liver 
PM 
54 
I3 
48 
52.W~ 
Hcpatoma 3924A 
PM 
47 
IO 
36 
43.9% 
Sigma) markedly inhibited this enzyme from 
both tissues. At hemoglobin concentrations of 
80 PM and higher a complete inhibition of the 
activity of both purified enzymes was observed. 
Methemoglobin was equally effective and myo- 
globin was also inhibitory; however, albumin, 
ferrous sulfate or ferric chloride in the same 
concentrations did not affect either enzyme activity. 
3.4. Inhibition bv NADPH 
NADPH is a powerful competitive inhibitor of 
normal liver G6P DH and the inhibition depends 
on the ratio of NADP+/NADPH [13]. Table 1 
shows that both liver and hepatoma purified 
G6P DH was inhibited to a similar extent by 
NADPH in a reaction mixture where the 
concentration of NADP was constant (21.6 PM). 
At a NADPH/NADP+ ratio of 8.6 the inhibition 
for liver and hepatoma enzymes was 52.5 and 
43.9%, respectively. 
3.5. Immunochemical studies 
The antiserum produced against the purified 
liver enzyme reacted with both the crude and 
purified G6P DH preparations from normal 
liver and hepatoma 3924A, resulting in a single 
precipitine line that fused and was stained for G6P 
DH activity. Similar reactions were observed 
with antiserum against purified enzyme from 
hepatomas 3924A or 7777. 
3.6. Titration of liver and hepatoma supernate G6P 
DH activity by liver G6P DH antisemm 
The immunodiffusion studies showed that the 
purified C6P DH from liver and hepatoma were 
immunologically identical (fig.l). Neutralization 
studies demonstrated that with suitable concen- 
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tration of the antiserum both liver and tumor 
G6P DH activities were completely neutralized. The 
fact that the slopes of the neutralization lines were 
similar supports the evidence of the immuno- 
diffusion studies indicating that the enzymes are 
identical. Although valuable studies have been 
carried out with immunochemical techniques on 
the behavior of G6P DH in rat liver [6,14,15] , 
the present report appears to be the first on the 
application of this method to the examination of 
the concentration of this enzyme in neoplastic 
liver. The representative xperiment reported in 
fig. 1 also indicated that the G6P DH specific 
Pig.1. Immunochemical titration of G6P DH from rat liver 
and hepatoma 3924A supernatcs. Duplicate samples were 
incubated in the presence of different amounts of antiserum 
in Tris buffer (5 mM, pH 8.0) for 45 min at 37’C and 
stored overnight at S°C. The supernates were centrifuged 
at 40 000 g for 20 min and assayed for the enzyme activity. 
Each point rcprescnts the average of two duplicate 
determinations. 
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activity purified from hepatoma 3924A was 
approx. 5fold of that isolated from the normal 
liver here by the same procedure. In turn, the 
hepatoma extract required about 5 times more 
antiserum for complete neutralization of the 
G6P DH activity than was necessary for the 
normal liver. Thus, in the hepatoma 3924A there 
was a S-fold increase in G6P DH concentration. 
3.7. hcreascd GfiP DH amount in hepatoma: 
evidence for reprogramming of gene expression 
in cancer cells 
The objective of these investigations was to 
analyze the evidence for an increase in the activity 
of gene expression in hepatomas as manifested in 
production of an increased amount of the specific 
catalytic protein, G6P DH. Earlier studies from 
this Laboratory indicated that the G6P DH activity, 
as determined in crude extracts in a spectrum of 
hepatomas of vastly different growth rates 
[8,16,17] , was increased in every neoplasm. The 
observations in talbe 1 and fig. 1 provided evidence 
that the purified G6P DH from rat liver and rapidly 
growing hepatoma 3924A was immunologically 
identical and the enzyme concentration was 
S-fold elevated in this tumor. Kinetic studies of 
the purified enzyme from liver and hepatoma 
3924A further confirm that the enzyme 
preparations were indistinguishable on the basis 
of kinetic properties for substrates and 
inhibitors. 
An isotope estimation of the overall behavior of 
the oxidative pathway of pentose phosphate bio+ 
synthesis indicated that there was an increased 
potential in the operation of this pathway in the 
hepatomas, especially in the rapidly growing tumors 
such as hepatoma 3924A (18). These isotope data 
are in line with the increased potential provided 
by increased concentration of G6P DH which is 
the rate-limiting enzyme of the direct oxidative 
pathway [8,16,17]. 
4. Conclusions 
The results obtained in these studies by 
employment of independent techniques for 
measuring enzyme concentrations support the 
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interpretation that the alteration in the biochemical 
pattern of tumor cells entails, in part, a 
reprogramming of gene expression. Earlier work 
demonstrated that the proliferation-linked enzyme 
phosphofructokinase was increased in concentration 
in hepatomas [3,4]. The present study provides 
evidence that the transformation-linked enzyme, 
G6P DH, was also increased in concentration in 
the hepatoma. This imbalance in gene expression 
coupled with an increased activity of transaldolase 
(EC 2.2.1.2) [ 171, phosphoribosylpyrophosphate 
synthetase (EC 2.7.6.1) [ 191, and glutamine 
phosphoribosylpyrophosphate amidotransferase 
(EC 2.4.2.14) [20,21] increase the potential of the 
tumors to channel metabolitcs into purine and 
pyrimidine biosynthesis. This pattern of 
reprogramming ene expression should provide 
selective advantages for the cancer cells. 
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